Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells

Immunology

Volumn 127, Issue 2, 2009, Pages 216-225

  Li, Xiangming ^a   Chen, Guangwu ^b   Garcia Navarro, Raquel ^a   Franck, Richard W ^b   Tsuji, Moriya ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

C glycoside; CD1d; Mouse and human iNKT cells; T helper 1 type response

Indexed keywords

ALKENE; ALPHA GALACTOSYLCERAMIDE; LIGAND; LIPID; SUGAR;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CARBOHYDRATE ANALYSIS; CELL ACTIVATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SCREENING; TH1 CELL;

ADULT; AGED; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1D; CELL DIFFERENTIATION; CELL LINE; CYTOKINES; DENDRITIC CELLS; FEMALE; GLYCOLIPIDS; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MIDDLE AGED; MONOSACCHARIDES; NATURAL KILLER T-CELLS; SPLEEN; TH1 CELLS; YOUNG ADULT;

EID: 65449169177     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2008.02943.x     Document Type: Article

References (26)

1. Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 2004 114 : 1379 88. (Pubitemid 40385565)
2. Yu KO, Porcelli SA. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy. Immunol Lett 2005 100 : 42 55. (Pubitemid 41262033)
3. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y, Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999 163 : 4647 50. (Pubitemid 29501223)
4. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003 198 : 267 79. (Pubitemid 36987852)
5. Ishikawa A, Motohashi S, Ishikawa E et al. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2005 11 : 1910 7. (Pubitemid 40471857)
6. Giaccone G, Punt CJ, Ando Y et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002 8 : 3702 9. (Pubitemid 34273285)
7. Chang YJ, Huang JR, Tsai YC, Hung JT, Wu D, Fujio M, Wong CH, Yu AL. Potent immune-modulating and anticancer effects of NKT cell stimulatory glycolipids. Proc Natl Acad Sci USA 2007 104 : 10299 304. (Pubitemid 47185659)
8. Savage PB, Teyton L, Bendelac A. Glycolipids for natural killer T cells. Chem Soc Rev 2006 35 : 771 9.
9. Goff RD, Gao Y, Mattner J et al. Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc 2004 126 : 13602 3. (Pubitemid 39407224)
10. Fujii S, Shimizu K, Hemmi H et al. Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice. Proc Natl Acad Sci USA 2006 103 : 11252 7. (Pubitemid 44156505)
11. Franck RW, Tsuji M. Alpha-c-galactosylceramides: synthesis and immunology. Acc Chem Res 2006 39 : 692 701.
12. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 2003 198 : 1631 41. (Pubitemid 37494156)
13. Lu X, Song L, Metelitsa LS, Bittman R. Synthesis and evaluation of an alpha-C-galactosylceramide analogue that induces Th1-biased responses in human natural killer T cells. Chembiochem 2006 7 : 1750 6.
14. Chen G, Chien M, Tsuji M, Franck RW. E and Z alpha-C-galactosylceramides by Julia-Lythgoe-Kocienski chemistry: a test of the receptor-binding model for glycolipid immunostimulants. Chembiochem 2006 7 : 1017 22. (Pubitemid 44049433)
15. Kinjo Y, Wu D, Kim G et al. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 2005 434 : 520 5. (Pubitemid 40477061)
16. Fujii S, Shimizu K, Steinman RM, Dhodapkar MV. Detection and activation of human Valpha24+ natural killer T cells using alpha-galactosyl ceramide-pulsed dendritic cells. J Immunol Methods 2003 272 : 147 59. (Pubitemid 36050752)
17. Borg NA, Wun KS, Kjer-Nielsen L et al. CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 2007 448 : 44 9. (Pubitemid 47037002)
18. Koch M, Stronge VS, Shepherd D et al. The crystal structure of human CD1d with and without alpha-galactosylceramide. Nat Immunol 2005 6 : 819 26. (Pubitemid 43090468)
19. Zajonc DM, Cantu C 3rd., Mattner J, Zhou D, Savage PB, Bendelac A, Wilson IA, Teyton L. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol 2005 6 : 810 8. (Pubitemid 43090467)
20. White D, Anthony J, Oyefeso A. Computational measurement of steric effects: the size of organic substituents computed by ligand repulsive energies. J ORG CHEM 1999 64 : 7707 16. (Pubitemid 29493693)
21. Fujio M, Wu D, Garcia-Navarro R, Ho DD, Tsuji M, Wong CH. Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity. J Am Chem Soc 2006 128 : 9022 3. (Pubitemid 44078971)
22. Oki S, Chiba A, Yamamura T, Miyake S. The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 2004 113 : 1631 40. (Pubitemid 39071687)
23. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001 413 : 531 4. (Pubitemid 32938752)
24. Chiba A, Oki S, Miyamoto K, Hashimoto H, Yamamura T, Miyake S. Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide. Arthritis Rheum 2004 50 : 305 13. (Pubitemid 38084316)
25. Yu KO, Im JS, Molano A et al. Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci USA 2005 102 : 3383 8. (Pubitemid 40328054)
26. Silk JD, Salio M, Reddy BG et al. Cutting edge: nonglycosidic CD1d lipid ligands activate human and murine invariant NKT cells. J Immunol 2008 180 : 6452 6.